Infectious Vaccination in Immunocompromised Children

Vaccination in Immunocompromised Children Vaccination is a cornerstone of preventive medicine, significantly reducing morbidity and mortality from infectious diseases. However, immunocompromised children-those with primary immunodeficiencies, cancer, organ transplants, or HIV-face unique challenges in achieving vaccine-induced immunity. Balancing safety and efficacy is critical in this population, as their immune systems may not respond adequately to standard vaccination protocols, and live-attenuated vaccines may pose risks. Immunocompromised children are at heightened risk for vaccine-preventable diseases due to impaired immune responses. Inactivated vaccines, such as those for influenza, pneumococcus, and hepatitis B, are generally safe but may yield suboptimal immunogenicity. For example, studies show that children undergoing chemotherapy for leukemia have reduced seroconversion rates to influenza vaccines, necessitating booster doses or alternative strategies. Conversely, live- attenuated vaccines, like measles-mumps-rubella (MMR) or varicella, are contraindicated in severely immunocompromised patients due to the risk of vaccine-associated disease. The Advisory Committee on Immunization Practices (ACIP) recommends avoiding these vaccines in children with T-cell deficiencies or those on high-dose immunosuppressive therapy. Tailored vaccination schedules are essential. For instance, children with HIV may receive MMR if their CD۴ counts are above a specific threshold, as determined by age-specific guidelines. Post-transplant patients often require revaccination due to waning immunity, with inactivated vaccines administered ۶-۱۲ months after transplantation, depending on immunosuppression levels. Additionally, household contacts of immunocompromised children should be fully vaccinated to provide herd immunity, reducing the risk of exposure to pathogens like pertussis or measles. Emerging research explores novel approaches, such as adjuvanted vaccines or mRNA platforms, to enhance immunogenicity in this group. For example, mRNA COVID-۱۹ vaccines have shown promise in immunocompromised populations, though booster doses are often required. Clinicians must weigh vaccine timing, disease risk, and immune status, often consulting specialists to optimize schedules. In conclusion, vaccinating immunocompromised children demands individualized strategies to ensure safety and efficacy. Ongoing research and updated guidelines are vital to improving outcomes in this vulnerable population, protecting them from preventable infections while minimizing risks.